27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
PLx Pharma Inc (NASDAQ:PLXP) recently raised $15 million in gross proceeds by issuing convertible preferred stock financing.
The capital raise is significantly more dilutive than was previously anticipated, which indicates that future fundraising for a successful Vazalore launch may be on less favorable terms, according to Raymond James.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The Analyst
Analyst Elliot Wilbur on Monday downgraded PLx Pharma from Outperform to Market Perform.
The Thesis
According to the recent capital raise terms, the shares will be convertible into common shares at a conversion price of $2.60 per share, with a potential stock dividend rate of 8 percent per annum or $1.2 million, Wilbur said in a Monday downgrade note.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
The dividend will stop accruing when the FDA approves Vazalore’s sNDA, which is likely to be in mid-2020, the analyst said.
The agreement includes the issuance of warrants that allow participants to purchase 500,000 shares of common stock at a price of $3.50 each. The combined effect of this could add about 6.2 million shares to the current outstanding share count and take the price point 50 percent below what was previously anticipated, Wilbur said.
The initial launch and marketing will require significant funding for shelf space and brand awareness, he said.
Future capital raises will likely not be as favorable given a tightening capital market, Wilbur said.
Raymond James reduced its 2026 Vazalore sales estimate from $206 million to $182 million.
Related Links:
55 Biggest Movers From Yesterday
The Daily Biotech Pulse: Tracon Aces Early-Stage Trials, Boston Scientific To Buy Out Millipede
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.